How big is Lifestance Health Group, Inc.?

As of Jun 18, Lifestance Health Group, Inc. has a market capitalization of 1,959.93 million and reported net sales of 1,283.50 million with a net profit of -35.64 million. Shareholder's funds were 1,446.29 million, and total assets were 2,227.04 million.

As of Jun 18, Lifestance Health Group, Inc. has a market capitalization of 1,959.93 million, categorizing it as a Small Cap company.<BR><BR>As of Jun 18, the company reported net sales of 1,283.50 million for the latest four quarters. During the same period, Lifestance Health Group, Inc. experienced a net profit of -35.64 million.<BR><BR>As of Dec 24, the company's shareholder's funds amounted to 1,446.29 million, while total assets were reported at 2,227.04 million.

What does Lifestance Health Group, Inc. do?

Lifestance Health Group, Inc. is a small-cap company in the Pharmaceuticals & Biotechnology industry, reporting net sales of $333 million and a net profit of $1 million as of March 2025. Key metrics include a market cap of $1.96 billion, a debt-to-equity ratio of 0.14, and a return on equity of -2.24%.

Overview: <BR>Lifestance Health Group, Inc. operates in the Pharmaceuticals & Biotechnology industry and is categorized as a small-cap company.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: 333 Million (Quarterly Results - Mar 2025) <BR>Most recent Net Profit: 1 Million (Quarterly Results - Mar 2025) <BR>Market-cap: USD 1,959.93 Million (Small Cap)<BR><BR>Key Metrics: <BR>P/E: NA (Loss Making) <BR>Industry P/E: NA <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.14 <BR>Return on Equity: -2.24% <BR>Price to Book: 1.35<BR><BR>Contact Details: <BR>Registrar Address: Not available.

Should I buy, sell or hold Lifestance Health Group, Inc.?

Is Lifestance Health Group, Inc. overvalued or undervalued?

As of November 8, 2021, Lifestance Health Group, Inc. is considered a risky investment due to its overvaluation, negative P/E ratio, poor returns on capital, and significant underperformance compared to the S&P 500.

As of 8 November 2021, the valuation grade for Lifestance Health Group, Inc. moved from does not qualify to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued, given its significant negative P/E ratio and poor returns on capital, with a Price to Book Value of 1.56, an EV to EBITDA of 49.80, and an EV to Sales ratio of 1.92. In comparison, peers such as Encompass Health Corp. have a more favorable P/E of 20.94 and an EV to EBITDA of 12.89, while The Ensign Group, Inc. shows a P/E of 32.46 and an EV to EBITDA of 21.10, highlighting the substantial gap in valuation metrics.<BR><BR>The company's stock has underperformed against the S&P 500, with a year-to-date return of -27.14% compared to the index's 12.22%, and a one-year return of -20.33% versus 17.14% for the S&P 500. This trend reinforces the notion that Lifestance Health Group, Inc. is not only overvalued but also struggling to deliver returns relative to broader market benchmarks.

Is Lifestance Health Group, Inc. technically bullish or bearish?

As of October 31, 2025, Lifestance Health Group, Inc. is in a bearish trend with weak strength indicators, having underperformed the S&P 500 significantly with a year-to-date return of -32.43% compared to the index's 16.30%.

As of 31 October 2025, the technical trend for Lifestance Health Group, Inc. has changed from mildly bearish to bearish. The current stance is bearish with weak strength indicated by the daily moving averages and the monthly MACD being bearish. The weekly MACD shows a mildly bullish signal, but this is offset by the overall bearish indicators from the Bollinger Bands and Dow Theory, both of which are mildly bearish on a weekly and monthly basis. <BR><BR>In terms of performance, the stock has underperformed significantly against the S&P 500 across multiple periods, with a year-to-date return of -32.43% compared to the S&P 500's 16.30%, and a one-year return of -26.87% versus 19.89% for the index.